Significant progress has been made with the discovery of ESR1 mutations, which are detectable in less than 1% of primary BC, but are enriched in metastatic luminal BC during adjuvant ET (in up to 15%–30%) and lead to ligand-independent autocrine tumor cell growth. Here, ESR1 is linked to neoplasm.